Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Product Type (Hemostats (Thrombin Based, Combination Hemostats, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based), Internal Tissue Sealants (Fibrin Based, Collagen Based, Protein Based, Synthetic Polymer Based), Adhesion Barriers (Film Based, Gel Based, Solution Based)), By Application (Surgical Applications (Cardiovascular Surgeries, Neurological Surgeries, Orthopedic Surgeries, Urological & Gynecological Surgeries, General Surgeries, Reconstructive, and Plastic Surgeries, Others), Trauma Cases), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

A surgical hemostat is a surgical tool used to control bleeding. It is common in the initial phases of surgery for the initial incision to be lined with hemostats that close blood vessels awaiting ligation. Internal tissue sealants are absorbable materials used to control internal bleeding by sealing the tissue. Thus, they can prevent leaks of fluid from the surgical incision. These are surgical glues and adhesives used for attaching tissue to one other to help in repair. While, adhesion barriers are the medical implants used to prevent the formation of internal adherence between tissues, and organs when they are healing. Drugs and materials such as animal membranes, gold foil, mineral oil, sheets of rubber, and Teflon are used to reduce the risk of adhesion formation. These three surgical materials are used to control bleeding during and after surgical procedures.

Market Dynamics

Increasing incidences of accidents and burns, increasing prevalence of cardiovascular diseases, and approvals of new products by regulatory authorities are attributed to the growth of the global surgical hemostats, internal tissue sealants, and adhesion barriers market. For instance, on February 23, 2021, EndoClot Plus Inc., a U.S.-based medical device company, received U.S. Food and Drug Administration approval (FDA) for its product EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that helps to stop gastrointestinal bleeding rapidly and reliably. EndoClot PHS is a single-use device including a starch-based powder hemostat that is applied directly to the bleeding site through a flexible endoscope. The Absorbable Modified Polymer (AMP) powder can quickly concentrate the blood to accelerate the normal physiological clotting process. A gelled matrix forms when the AMP powder contacts blood or fluid in the GI tract to provide a mechanical barrier to further control bleeding.

Key features of the study:

• This report provides an in-depth analysis of the global surgical hemostats, internal tissue sealants, and adhesion barriers market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global surgical hemostats, internal tissue sealants, and adhesion barriers market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ethicon (Johnson & Johnson), Baxter International Inc., Integra LifeSciences Holdings Corporation, Pfizer Inc., Tissuemed Ltd., Sanofi, Braun Melsungen AG, C.R. Bard, Inc., CryoLife, Inc., Cohera Medical, Inc., and CSL Behring
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global surgical hemostats, internal tissue sealants, and adhesion barriers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global surgical hemostats, internal tissue sealants, and adhesion barriers market.

Detailed Segmentation:

• Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Product Type:
• Hemostats
• Thrombin Based
• Combination Hemostats
• Oxidized Regenerated Cellulose Based
• Gelatin Based
• Collagen Based
• Internal Tissue Sealants
• Fibrin Based
• Collagen Based
• Protein Based
• Synthetic Polymer Based
• Adhesion Barriers
• Film Based
• Gel Based
• Solution Based
• Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Application:
• Surgical Applications
• Cardiovascular Surgeries
• Neurological Surgeries
• Orthopedic Surgeries
• Urological & Gynecological Surgeries
• General Surgeries
• Reconstructive and Plastic Surgeries
• Others
• Trauma Cases
• Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By End User:
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Company Profiles
• Ethicon (Johnson & Johnson)
• Baxter International Inc.
• Integra LifeSciences Holdings Corporation
• Pfizer Inc.
• Tissuemed Ltd.
• Sanofi
• Braun Melsungen AG
• C.R. Bard, Inc.
• CryoLife, Inc.
• Cohera Medical, Inc.
• CSL Behring